First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

• Ngā kaituhi matua: Qiao Liu (Author), Zhen Zhou (Author), Xia Luo (Author), Lidan Yi (Author), Liubao Peng (Author), Xiaomin Wan (Author), Chongqing Tan (Author), Xiaohui Zeng (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2021-12-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1(PD-L1) expression of at least 50%. This study was de...